Targeted therapy for cancer in India
Targeted therapy attacks a specific fault inside cancer cells rather than attacking all fast-dividing cells the way chemotherapy does. That makes it more precise and often better tolerated, but it only works if your cancer actually carries the fault the drug targets. Testing comes first, always.
- How it differs
- Aims at a specific molecular fault, not at all dividing cells
- Testing is essential
- Without the right marker, the drug will not work. No exceptions
- Forms
- Daily tablets, or antibodies given by drip
- Common targets
- HER2, EGFR, ALK, BRAF, BRCA/PARP, VEGF, and many more
- Resistance
- Cancers often adapt over time. Later-generation drugs may follow
- Cost
- Expensive, but biosimilars in India reduce it substantially
How it differs from chemotherapy
Chemotherapy works on a simple principle: cancer cells divide faster than most healthy cells, so a drug that poisons dividing cells hits cancer harder. It is effective and it is blunt, which is why it also affects hair, gut lining and bone marrow.
Targeted therapy works differently. Researchers identify a specific broken mechanism the cancer depends on, often a faulty protein driving its growth, and design a drug that blocks precisely that mechanism. Healthy cells, which do not depend on the faulty protein, are largely unaffected.
The consequence is the thing to understand: if your cancer does not have the target, the drug does nothing. Not a little, nothing. This is why testing your tumour is not optional administration before treatment; it is the treatment decision itself.
The testing that decides everything
Molecular or biomarker testing is performed on tumour tissue from your biopsy, or sometimes on a blood sample known as a liquid biopsy where tissue is not available. It looks for the specific changes that particular drugs act on.
If you are travelling for treatment, this matters practically. Testing takes time, often one to three weeks, and it can frequently be done on your existing biopsy sample without a new procedure. Sending your reports in advance so testing can begin before you travel may save you weeks. Ask in your consultation whether testing has been done, what it showed, and whether wider sequencing would add anything.
Common targets, and which cancers they apply to
| Target | Mainly in | What it means for you |
|---|---|---|
| HER2 | Breast, stomach, some others | Antibody drugs added to chemotherapy improve results |
| EGFR | Lung cancer | A daily tablet can control the cancer well, often for a long period |
| ALK / ROS1 | Lung cancer | Tablets with strong response rates in the small group who carry it |
| BRCA / HRD | Ovarian, breast, prostate, pancreatic | PARP inhibitor tablets, often as maintenance after chemotherapy |
| BRAF | Melanoma, some colorectal and thyroid | Combination tablets that can shrink disease quickly |
| VEGF | Colorectal, kidney, lung, ovarian | Cuts off the tumour's blood supply, usually alongside chemotherapy |
| Hormone receptors | Breast, prostate | The oldest form of targeted treatment, and still among the most effective |
Side effects: better tolerated, not harmless
Most people find targeted therapy easier than chemotherapy in daily life. Hair loss is usually not a feature, and severe nausea is uncommon. But these drugs have their own characteristic effects, which vary by target: skin rash and diarrhoea are common with EGFR drugs, high blood pressure and poor wound healing with VEGF drugs, and some antibody drugs need heart monitoring.
Because many are taken as daily tablets over long periods, side effects need managing rather than simply enduring, and dose adjustments are often possible. Ask what specifically to expect from your drug, and who you contact once you are home.
Resistance, and why it is not the end
Targeted therapy often works well and then stops working. The cancer adapts, developing a new change that bypasses the blocked mechanism. This is expected rather than a failure of your treatment.
What usually follows is repeat testing to identify the new change, then a later-generation drug designed for exactly that resistance, or a switch to another approach. Lung cancer treatment in particular now has sequences of drugs used one after another. Knowing this in advance makes the conversation about "what if it stops working" much less frightening.
Cost, and why India makes a real difference here
Targeted drugs are expensive everywhere, and because they are taken for months or years, the total is often the largest part of a treatment plan. This is where India offers something genuinely different rather than only cheaper.
India has a substantial biosimilar and generic pharmaceutical industry, and approved biosimilar versions of several major targeted drugs are available at a fraction of the originator price. For long-term treatment that difference compounds considerably. Ask your oncologist which version is being proposed and what the monthly cost is, and get it in writing, because this is the number that will matter most to you over the following year. You receive a written estimate before you commit, with no fee to us built in; the hospital pays us, so your bill is never marked up.
Questions patients ask
Is targeted therapy better than chemotherapy?
Where your cancer carries the right target, it is often more effective and better tolerated. Where it does not, the drug does nothing at all and chemotherapy is the better treatment. They are also frequently used together. Testing, not preference, decides which applies.
How do I know if targeted therapy will work for me?
Only by testing your tumour tissue, or sometimes blood, for the specific markers that particular drugs act on. If molecular testing has not been done on your biopsy, that is the first thing to ask about. Sending your reports before travelling lets testing start earlier and can save weeks.
Is it the same as immunotherapy?
No. Targeted therapy blocks a specific faulty mechanism inside cancer cells. Immunotherapy releases the brakes on your immune system so your own body attacks the cancer. Different mechanisms, different side effects, and different predictive tests, though both are sometimes used in the same plan.
Will I lose my hair?
Usually not. Hair loss is characteristic of chemotherapy rather than targeted therapy. Some targeted drugs cause hair thinning or changes in texture, and skin and nail changes are fairly common with certain classes, but general hair loss is not typical.
What happens when it stops working?
Cancers commonly develop resistance over time, and this is anticipated. Repeat testing identifies the new change, and a later-generation drug designed for that resistance may be available, or treatment switches to another approach. In lung cancer especially, sequences of successive targeted drugs are now standard practice.
Are biosimilars as good as the original drug?
Approved biosimilars must demonstrate equivalent effectiveness and safety to the originator through regulatory review. India has a well-established biosimilar industry, which is why several major targeted drugs cost far less here. Ask your oncologist specifically which version is proposed and confirm it is an approved product.
Can I continue treatment at home?
Often yes, particularly for tablet-based drugs. Many international patients have testing and the treatment plan established in India, then continue at home with monitoring arranged locally. Establish that arrangement before you begin, including who reviews your blood tests and who you contact if side effects appear.
Related
- Chemotherapy in India
- Immunotherapy in India
- Lung cancer treatment in India: EGFR and ALK
- Breast cancer treatment in India: HER2 and hormone therapy
- Ovarian cancer treatment in India: BRCA and PARP